Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. (MDNA.TO) Revenue
Annual & quarterly revenue history · segment & region breakdown
MDNA.TO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsMedicenna Therapeutics Corp. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-03-31 | $0.00B | +$0.00B | — |
| 2024-03-31 | $0.00B | +$0.00B | — |
| 2023-03-31 | $0.00B | +$0.00B | — |
| 2022-03-31 | $0.00B | +$0.00B | — |
| 2021-03-31 | $0.00B | +$0.00B | — |
| 2020-03-31 | $0.00B | +$0.00B | — |
| 2019-03-31 | $0.00B | +$0.00B | — |
| 2018-03-31 | $0.00B | +$0.00B | — |
| 2017-03-31 | $0.00B | +$0.00B | — |
| 2016-03-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Medicenna Therapeutics Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Medicenna Therapeutics Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Medicenna Therapeutics Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MDNA.TO revenue · 4 questionsMDNA.TO's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Medicenna Therapeutics Corp. SEC filings · GAAP · Medicenna Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026